Status:
NOT_YET_RECRUITING
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Lead Sponsor:
Fudan University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospecti...
Detailed Description
1. Overall Design: This trial is a single-center, prospective, single-arm, phase II clinical trial to evaluate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib fo...
Eligibility Criteria
Inclusion
- Age≥18 years old;
- Sign the informed consent form;
- Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer.
- Tumor recurrence or progression within 6 months after using platinum-based drugs;
Exclusion
- Any uncontrolled medical condition that may put the patient at high risk during treatment .
- Receipt of any other investigational medicinal product within the last 30 days before randomization.
- Patients with ovarian cancer excluded by pathological or clinical diagnosis;
- Physical intolerance patients;
- Patients who are unwilling to participate in the clinical trial.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06552858
Start Date
September 1 2024
End Date
January 31 2027
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Shanghai, Shanghai Municipality, China, 200000